Mavyret

DRUG5 trials

Sponsors

University of Pennsylvania, Massachusetts General Hospital, NYU Langone Health, Mayo Clinic, Duke University

Conditions

Chronic Hepatitis CChronic Kidney DiseaseEnd Stage Renal DiseaseHeart Transplant InfectionHepatitis CHivKidney Transplant; ComplicationsOpioid Use

Phase 1

Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients

CompletedNCT02743897

University of PennsylvaniaEnd Stage Renal Disease

Start: 2016-05-01End: 2022-12-31Updated: 2023-06-15

Phase 2

A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret

CompletedNCT03523871

NYU Langone HealthHepatitis C

Start: 2018-05-12End: 2020-09-01Updated: 2021-09-05

Phase 4

Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C

CompletedNCT02946034

Massachusetts General HospitalChronic Hepatitis C, Chronic Kidney Disease

Start: 2017-02-01End: 2020-09-16Updated: 2021-11-05

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

Active, not recruitingNCT04508907

Mayo ClinicHeart Transplant Infection, Hepatitis C, Kidney Transplant; Complications

Start: 2020-09-10End: 2026-11-01Target: 200Updated: 2025-12-17

Unknown Phase

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

CompletedNCT05108935

Duke UniversityHepatitis C, Hiv, Opioid Use +2

Start: 2022-02-17End: 2023-03-30Updated: 2023-04-27

Related Papers

Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial.

2018-08-07166 citations